Clinical Research on Retinal Neovascularization of Diabetic Retinopathy

This study has been terminated.
Sponsor:
Information provided by:
Tianjin Medical University
ClinicalTrials.gov Identifier:
NCT01229540
First received: October 26, 2010
Last updated: NA
Last verified: September 2008
History: No changes posted
  Purpose

Retinal neovascularization of diabetic retinopathy might be associated with genetic risk factors and environmental risk factors.


Condition Intervention
The Mechanism of Retinal Neovascularization of Diabetic
Retinopathy.
Genetic: genetic analyzer

Study Type: Interventional

Resource links provided by NLM:


Further study details as provided by Tianjin Medical University:

Arms Assigned Interventions
No Intervention: Lifestyle counseling Genetic: genetic analyzer

  Eligibility

Ages Eligible for Study:   45 Years to 74 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • T2DM was diagnosed according to the World Health Organization Expert Consultation Report 1999 and consisted of one of the following: fasting blood glucose (FBG) ≥7.0 mmol/L (≥126 mg/dL), blood glucose ≥11.1 mmol/L (≥200 mg/dL) 2 hours after an oral glucose tolerance test (OGTT); or a random blood glucose ≥11.1 mmol/L (≥200 mg/dL).
  • DR was clinically graded in accordance with the International Clinical Diabetic Retinopathy guidelines based on fundus fluorescence angiography.
  • All participants with PDR underwent a comprehensive dilated fundus examination to detect DR by indirect ophthalmoscopy and were diagnosed by fundus fluorescence angiography.

Exclusion Criteria:

  • Patients were excluded if they had acute complications of diabetes mellitus, type 1 diabetes mellitus, other types of diabetes, serious cardiovascular, hepatic, nephritic or other complications, other serious primary diseases or mental illness.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01229540

Locations
China, Tianjin
Tianjin Eye Hospital, Clinical college of Ophthalmology ,Tianjin Medical Univercity
Tianjin, Tianjin, China, 300020
Sponsors and Collaborators
Tianjin Medical University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT01229540     History of Changes
Other Study ID Numbers: 08ZCGYSF01700, 08ZCGYSF01700
Study First Received: October 26, 2010
Last Updated: October 26, 2010
Health Authority: China: Ethics Committee

Additional relevant MeSH terms:
Diabetic Retinopathy
Neovascularization, Pathologic
Retinal Diseases
Retinal Neovascularization
Eye Diseases
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Metaplasia
Pathologic Processes

ClinicalTrials.gov processed this record on July 22, 2014